

CITATION REPORT

List of articles citing

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

DOI: 10.1016/s1470-2045(16)00172-8
Lancet Oncology, The, 2016, 17, 801-810.

Source: <https://exaly.com/paper-pdf/64102744/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
628	Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. 2016 , 12, 924-925		
627	Clinical Decision-Making in Pancreatic Cancer. 2016 , 1-32		
626	Arterial Resection in Pancreatic Cancer. 2016 , 1-16		1
625	Treatment of Recurrent Pancreatic Cancer After Surgery 2016 , 1-26		
624	Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer. 2016 , 13, 750-765		137
623	Pancreatic cancer: Clinical practice guidelines - what is the evidence?. 2016 , 13, 593-4		10
622	Locally advanced pancreatic cancer: maybe not so local. <i>Lancet Oncology, The</i> , 2016 , 17, 694-695	21.7	2
621	Inhibition of group 1 p21-activated kinases suppresses pancreatic stellate cell activation and increases survival of mice with pancreatic cancer. 2017 , 140, 2101-2111		26
620	Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. 2017 , 23, 753-759		15
619	Multi-disciplinary management of locally advanced pancreatic cancer with irreversible electroporation. 2017 , 116, 35-45		8
618	Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. <i>Lancet Oncology, The</i> , 2017 , 18, 770-778	21.7	120
617	What treatment in 2017 for inoperable pancreatic cancers?. 2017 , 28, 1473-1483		22
616	Pancreatic Cancer. 2017 ,		1
615	Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?. 2017 , 11, 683-694		4
614	Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?. 2017 , 24, 1406-1413		41
613	Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer. 2017 , 123, 3816-3824		30
612	Surgical strategies and novel therapies for locally advanced pancreatic cancer. 2017 , 116, 16-24		12

611	Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. 2017 , 6, 1201-1219	82
610	Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study. 2017 , 24, 2734-2743	58
609	Press review. 2017 , 154, 51-58	
608	A phase 1 study of gemcitabine/nab-paclitaxel/S-1 (GAS) combination neoadjuvant chemotherapy for patients with locally advanced pancreatic adenocarcinoma. 2017 , 79, 775-781	20
607	Risk-stratified versus Non-Risk-stratified Diagnostic Testing for Management of Suspected Acute Biliary Obstruction: Comparative Effectiveness, Costs, and the Role of MR Cholangiopancreatography. 2017 , 284, 468-481	8
606	Underestimation of pancreatic cancer in the national cancer registry - Reconsidering the incidence and survival rates. 2017 , 72, 186-191	37
605	Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. 2017 , 161, 939-950	77
604	Pancreatic cancer: Current status and Challenges. 2017 , 3, 396-408	12
603	Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. 2017 , 28, 2786-2792	57
602	Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions. 2017 , 10, 631-645	26
601	Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. 2017 , 17, 951-964	1
600	Nationwide outcomes in patients undergoing surgical exploration without resection for pancreatic cancer. 2017 , 104, 1568-1577	21
599	Recent Advances in Pancreatic Cancer Surgery. 2017 , 15, 520-537	10
598	Autophagy inhibition enhances antiproliferative effect of salinomycin in pancreatic cancer cells. 2017 , 17, 990-996	17
597	Improving outcomes in patients with resectable pancreatic cancer. 2017 , 104, 1421-1423	8
596	Modified-FOLFIRINOX in metastatic pancreatic cancer: A prospective study in Chinese population. 2017 , 406, 22-26	35
595	Actualizaci3n en c3ncer de p3ncreas y de v3as biliares. 2017 , 12, 1919-1928	
594	Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?. 2017 , 51, 1-10	7

593	Ablative Radiotherapy Doses for Locally Advanced: Pancreatic Cancer (LAPC). 2017 , 23, 350-354	9
592	Preoperative predictors for early recurrence of resectable pancreatic cancer. 2017 , 15, 16	48
591	Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study. 2017 , 48, 170-175	8
590	Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer. 2017 , 51, 184-192	12
589	Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. 2017 , 18,	49
588	Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells. 2017 , 5,	49
587	Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. 2017 , 15, 183	78
586	Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?. 2017 , 12, 203	8
585	Added value of CA19-9 response in predicting resectability of locally advanced pancreatic cancer following induction chemotherapy. 2018 , 20, 605-611	38
584	Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. 2018 , 28, 4265-4273	21
583	Pancreatic Adenocarcinoma Staging in the Era of Preoperative Chemotherapy and Radiation Therapy. 2018 , 287, 374-390	71
582	Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. 2018 , 25, 261-268	23
581	Palliative Chemotherapy for Advanced Pancreatic Cancer. 2018 , 872-878	
580	How to Reliably Assess Nodal Status in Distal Pancreatectomy for Adenocarcinoma. 2018 , 47, 308-313	7
579	[Early stage pancreatic cancer]. 2018 , 89, 257-265	1
578	Cure of unresectable, locally advanced pancreatic cancer after multidisciplinary therapy. 2018 , 5, 27-31	2
577	Clinical significance of defining borderline resectable pancreatic cancer. 2018 , 18, 139-145	5
576	Future Perspectives of IRE. 2018 , 271-280	

575	Medical oncology and pancreatic cancer: what the radiologist needs to know. 2018 , 43, 383-392	1
574	Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. 2018 , 61, 1576-1594	17
573	Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. 2018 , 4, 963-969	253
572	Clinical Decision-Making in Pancreatic Cancer. 2018 , 601-632	
571	Borderline Resectable Pancreatic Cancer. 2018 , 1001-1020	
570	Treatment of Recurrent Pancreatic Cancer After Surgery. 2018 , 1105-1130	
569	Arterial Resection in Pancreatic Cancer. 2018 , 1089-1104	
568	Neoadjuvant Chemotherapy in Pancreatic Cancer. 2018 , 1187-1202	1
567	Outcomes After Distal Pancreatectomy with Celiac Axis Resection for Pancreatic Cancer: A Pan-European Retrospective Cohort Study. 2018 , 25, 1440-1447	49
566	Staging pancreatic carcinoma by computed tomography. 2018 , 60, 10-23	3
565	Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer. 2018 , 17, 187-197	17
564	The Role of Venous and Arterial Resection in Pancreatic Cancer Surgery. 2018 , 25, 51-58	27
563	Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?. 2018 , 267, e35-e36	3
562	Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma. 2018 , 41, 982-985	10
561	Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. 2018 , 22, 235-241	29
560	Pharmacopigenetics and pharmacopigenomics of gastrointestinal cancers. 2018 , 12, 49-62	1
559	Staging pancreatic carcinoma by computed tomography. 2018 , 60, 10-23	4
558	The clinical benefit of hyperthermia in pancreatic cancer: a systematic review. 2018 , 34, 969-979	27

557	Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy. 2018 , 23, 4-e10	10
556	Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer. 2018 , 22, 288-294	4
555	Locally advanced pancreatic cancer: An emerging entity. 2018 , 42, 12-25	9
554	Recent advances in the management of pancreatic adenocarcinoma. 2018 , 18, 51-62	8
553	Technical aspects of modern radiation therapy for pancreatic adenocarcinoma: field design, motion management, dosing, and concurrent therapy. 2018 , 1, 21-21	1
552	Home-Based e-Health Platform for Multidimensional Telemonitoring of Symptoms, Body Weight, Sleep, and Circadian Activity: Relevance for Chronomodulated Administration of Irinotecan, Fluorouracil-Leucovorin, and Oxaliplatin at Home-Results From a Pilot Study. 2018 , 2, 1-15	14
551	Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. 2018 , 3, 80	20
550	Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection?. 2018 , 7, 289-291	1
549	Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. 2018 , 9, 982-988	6
548	Review and current state of radiation therapy for locally advanced pancreatic adenocarcinoma. 2018 , 9, 1027-1036	4
547	Revue de presse. 2018 , 155, 517-525	
546	Neoadjuvant Treatment for Nonmetastatic Pancreatic Cancer. 2018 ,	1
545	Comparison of efficacy and safety between standard-dose and modified-dose FOLFIRINOX as a first-line treatment of pancreatic cancer. 2018 , 10, 421-430	18
544	Chinesische Arzneitherapie bei Pankreaskarzinom. 2018 , 61, 256-257	
543	Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer: A single center experience. 2018 , 97, e13592	16
542	Comparison of different treatment planning approaches for intensity-modulated proton therapy with simultaneous integrated boost for pancreatic cancer. 2018 , 13, 228	13
541	Surgery for Pancreatic Cancer after neoadjuvant treatment. 2018 , 2, 413-418	29
540	Neoadjuvant and adjuvant chemotherapy in pancreatic cancer. 2018 , 403, 917-932	41

539	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. 2018 , 18, 1298	44
538	Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review. 2018 , 9, 21613-21627	29
537	21 Pancreatic Cancer. 2018 ,	
536	Press review. 2018 , 155, 503-510	
535	FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. 2018 , 118, 1021-1026	14
534	Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. 2018 , 25, 4027-4034	10
533	Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. 2018 , 9, 389-393	1
532	Response of patients with locally advanced pancreatic adenocarcinoma to high-intensity focused ultrasound treatment: a single-center, prospective, case series in China. 2018 , 10, 4439-4446	13
531	Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. 2018 , 118, 1277-1284	14
530	Trials and tribulations of neoadjuvant therapy in pancreatic cancer. 2018 , 105, 1387-1389	11
529	Overexpression of GP73 promotes cell invasion, migration and metastasis by inducing epithelial-mesenchymal transition in pancreatic cancer. 2018 , 18, 812-821	10
528	A single institutional experience of combined carbon-ion radiotherapy and chemotherapy for unresectable locally advanced pancreatic cancer. 2018 , 129, 333-339	22
527	Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. 2018 , 7, 4943-4951	16
526	Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). 2018 , 50, 1257-1271	65
525	Irreversible Electroporation in Pancreatic Cancer. 2018 ,	1
524	Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. 2018 , 25, 342-350	17
523	Neoadjuvant -paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. 2018 , 38, 4035-4039 ⁹	
522	Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. 2018 , 36, 1273-1284	6

521	Chemoradiotherapy versus chemotherapy for locally advanced unresectable pancreatic cancer: A systematic review and meta-analysis. 2018 , 14, 392-401	6
520	Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). 2018 , 18, 762	53
519	Clinical evaluation of intensity-modulated radiotherapy for locally advanced pancreatic cancer. 2018 , 13, 118	18
518	Benefit from the inclusion of surgery in the treatment of patients with stage III pancreatic cancer: a propensity-adjusted, population-based SEER analysis. 2018 , 10, 1907-1918	5
517	Contemporary Management of Localized Resectable Pancreatic Cancer. 2018 , 10,	35
516	[Role of radiation therapy in the management of pancreatic cancer]. 2018 , 22, 552-557	
515	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma. 2018 , 102, 95-102	32
514	Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. 2018 , 22, 1804-1810	19
513	Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort. 2018 , 403, 701-709	10
512	Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?. 2018 , 44, 1486-1493	7
511	Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study. 2018 , 16, 125	57
510	Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. 2018 , 8, 623-627	4
509	The Role of the Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma and Preclinical Models to Study It. 2018 , 735-748	
508	Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer. 2019 , 89, 481-487	18
507	Neue Standards in der adjuvanten Therapie des Pankreaskarzinoms?!. 2019 , 14, 126-128	
506	Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan. 2019 , 8,	4
505	Gastroenterology For General Surgeons. 2019 ,	1
504	Irreversible Electroporation: Expanding the Armamentarium against Pancreatic Cancer. 2019 , 03, 138-142	

503	Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis. 2019 , 10, 4420-4429	11
502	Acute Pancreatitis, Chronic Pancreatitis and Pancreatic Neoplasms. 2019 , 103-117	
501	Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer. 2019 , 37, 2643-2650	77
500	Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. 2019 , 19, 675	16
499	Analgesic Effect of Melittin on Oxaliplatin-Induced Peripheral Neuropathy in Rats. 2019 , 11,	17
498	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 2019 , 11,	19
497	Nanoenabled Reversal of IDO1-Mediated Immunosuppression Synergizes with Immunogenic Chemotherapy for Improved Cancer Therapy. 2019 , 19, 5356-5365	55
496	Locally Advanced Pancreatic Cancer: Work-Up, Staging, and Local Intervention Strategies. 2019 , 11,	37
495	Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. 2019 , 154, 932-942	55
494	The role of biological dose-escalation for pancreatic cancer. 2019 , 18, 128-130	17
493	Yield of staging laparoscopy before treatment of locally advanced pancreatic cancer to detect occult metastases. 2019 , 45, 1906-1911	9
492	An update on treatment options for pancreatic adenocarcinoma. 2019 , 11, 1758835919875568	73
491	Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer. 2019 , 9, 16187	8
490	Are We Sure that Adjuvant Chemotherapy is the Best Approach for Resectable Pancreatic Cancer? Are We in the Era of Neoadjuvant Treatment? A Review of Current Literature. 2019 , 8,	12
489	Conversion Surgery for Advanced Pancreatic Cancer. 2019 , 8,	10
488	Aktuelle Entwicklungen zur neoadjuvanten und adjuvanten Therapie des Pankreaskarzinoms. 2019 , 22, 260-267	
487	Targeting claudin-4 enhances chemosensitivity of pancreatic ductal carcinomas. 2019 , 8, 6700-6708	8
486	Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. 2019 , 166, 1017-1026	19

485	Clinical usefulness of conversion surgery for unresectable pancreatic cancer diagnosed on multidetector computed tomography imaging: Results from a multicenter observational cohort study by the Hokkaido Pancreatic Cancer Study Group (HOPS UR-01). 2019 , 3, 523-533	7
484	Pathogenese und Diagnostik beim Pankreaskarzinom. 2019 , 40, 165-170	
483	A Multicenter, Randomized Controlled Trial of Perioperative Palliative Care Surrounding Cancer Surgery for Patients and Their Family Members (PERIOP-PC). 2019 , 22, 44-57	9
482	[Relief of Obstruction in the Management of Pancreatic Cancer]. 2019 , 74, 69-80	
481	Transport-Mediated Oxaliplatin Resistance Associated with Endogenous Overexpression of MRP2 in Caco-2 and PANC-1 Cells. 2019 , 11,	8
480	Modulated Electro-Hyperthermia as Palliative Treatment for Pancreatic Cancer: A Retrospective Observational Study on 106 Patients. 2019 , 18, 1534735419878505	16
479	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan. 2019 , 18, e394-e401	7
478	First results from the Swedish National Pancreatic and Periampullary Cancer Registry. 2019 , 21, 34-42	23
477	CA19-9 elevation as an indication to start salvage treatment in surveillance after pancreatic cancer resection. 2019 , 19, 302-306	8
476	Circulating Biomarkers for Prediction of Objective Response to Chemotherapy in Pancreatic Cancer Patients. 2019 , 11,	12
475	Role of surgical resection in the era of FOLFIRINOX for advanced pancreatic cancer. 2019 , 26, 416-425	19
474	Safety of radiofrequency ablation in patients with locally advanced, unresectable pancreatic cancer: A phase II study. 2019 , 45, 2166-2172	10
473	Tumor-Derived Extracellular Vesicles Inhibit Natural Killer Cell Function in Pancreatic Cancer. 2019 , 11,	50
472	Ablative radiation therapy for locally advanced pancreatic cancer: techniques and results. 2019 , 14, 95	54
471	A Simple and Easily Reproducible Model of Reversible Obstructive Jaundice in Rats. 2019 , 33, 699-706	2
470	Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. 2019 , 5, 1020-1027	205
469	Pancreatic ductal adenocarcinoma and paraaortic lymph nodes metastases: The accuracy of intraoperative frozen section. 2019 , 19, 710-715	1
468	Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer. 2019 , 2019, 9346017	29

467	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. 2019 , 77, 1-10	26
466	International Study Group of Pancreatic Surgery type 3 and 4 venous resections in patients with pancreatic adenocarcinoma:the Paoli-Calmettes Institute experience. 2019 , 45, 1912-1918	9
465	Management of isolated recurrence after surgery for pancreatic adenocarcinoma. 2019 , 106, 898-909	17
464	Imaging response evaluation after novel neoadjuvant treatments of pancreatic cancer. 2019 , 51, 146-152	4
463	Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. 2019 , 11,	7
462	Management of ductal pancreatic cancer. 2019 , 51, 135-138	1
461	and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. 2019 , 11,	32
460	Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. 2019 , 111, 782-794	113
459	Treatment strategies and clinical outcomes of locally advanced pancreatic cancer patients treated at high-volume facilities and academic centers. 2019 , 4, 302-313	7
458	Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study. 2019 , 21, 1385-1392	10
457	FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. 2019 , 51, 1043-1049	5
456	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. 2019 , 43, 663-668	9
455	Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. 2019 , 19, 394	21
454	Surgical and local therapeutic concepts of oligometastatic pancreatic cancer in the era of effective chemotherapy. 2019 , 51, 153-164	2
453	Preoperative Imaging Evaluation after Downstaging of Pancreatic Ductal Adenocarcinoma: A Multi-Center Study. 2019 , 11,	14
452	Adjuvant chemotherapy and outcomes in patients with nodal and resection margin-negative pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. 2019 , 119, 932-940	8
451	Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective Analysis. 2019 , 11,	17
450	Chemotherapy for pancreatic cancer. 2019 , 48, e159-e174	65

449	Modified-FOLFIRINOX combined with deep regional hyperthermia in pancreatic cancer: a retrospective study in Chinese patients. 2019 , 36, 394-402	6
448	Aktuelle Entwicklungen zur neoadjuvanten und adjuvanten Therapie des Pankreaskarzinoms. 2019 , 25, 669-677	
447	Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club. 2019 , 14, 1-18	8
446	Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. 2019 , 49, 894-906	15
445	Impact of expanding indications on surgical and oncological outcome in 1434 consecutive pancreatoduodenectomies. 2019 , 21, 865-875	13
444	A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. 2019 , 21, 1024-1031	29
443	How I treat pancreatic cancer. 2020 , 4, e000818	4
442	Maintenance Therapy with FOLFIRI after FOLFIRINOX for Advanced Pancreatic Ductal Adenocarcinoma: A Retrospective Single-Center Analysis. 2019 , 2019, 5832309	8
441	Do we need sequential local therapy following neoadjuvant chemotherapy for locally advanced pancreatic cancer?. 2019 , 17, 100222	1
440	Induction Therapy in Localized Pancreatic Cancer. 2019 , 48, 913-919	3
439	Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination?. 2019 , 8, 61	8
438	Efficacy and feasibility of stereotactic radiotherapy after folfirinox in patients with locally advanced pancreatic cancer (LAPC-1 trial). 2019 , 17, 100200	22
437	Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist. 2019 , 36, 386-391	2
436	Biological characteristics of gene expression features in pancreatic cancer cells induced by proton and X-ray irradiation. 2019 , 95, 571-579	5
435	Neoadjuvant Treatment for Pancreatic Cancer. 2019 , 46, 19-27	50
434	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. 2019 , 24, 945-954	9
433	Clinico-pathological features and survival of patients with malignant exocrine pancreatic neoplasms: The AC Camargo Cancer Center experience. 2019 , 119, 71-78	0
432	Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. 2019 , 24, 301-e93	14

431	Induction chemotherapy in borderline (non-)resectable pancreatic cancer: a unique window of opportunity for understanding pancreatic cancer. 2019 , 106, 34-36	1
430	FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. 2019 , 19, 296-301	12
429	MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. 2019 , 9, 436-448	25
428	Optimizing the outcomes of pancreatic cancer surgery. 2019 , 16, 11-26	262
427	DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth. 2019 , 68, 1465-1476	27
426	How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. 2019 , 26, 109-117	36
425	Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer. 2019 , 19, 149-157	6
424	A Preoperative Prognostic Scoring System to Predict Prognosis for Resectable Pancreatic Cancer: Who Will Benefit from Upfront Surgery?. 2019 , 23, 990-996	13
423	Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. 2019 , 269, 733-740	151
422	A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers. 2019 , 50, 62-68	37
421	Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. 2019 , 270, 340-347	149
420	Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence. 2019 , 50, 285-291	6
419	Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC): An International Delphi Study Among Patients and Health Care Providers. 2019 , 270, 158-164	22
418	Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. 2020 , 271, 1137-1147	23
417	S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial. 2020 , 20, 133-138	4
416	Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival. 2020 , 22, 224-232	20
415	Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?: A Single Institution's Experience With 118 Patients. 2020 , 271, 932-940	62
414	The Potential to Source a Patient's Imaginative Powers in Treating Cancer: Illustrated in Three Cases. 2020 , 27, 55-60	

413	Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study. 2020 , 294, 212-220	40
412	Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study. 2020 , 27, 1986-1996	11
411	Surgical indication for and desirable outcomes of conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma. 2020 , 4, 6-13	22
410	Identification of a novel PAK1 inhibitor to treat pancreatic cancer. 2020 , 10, 603-614	7
409	Nationwide trends in incidence, treatment and survival of pancreatic ductal adenocarcinoma. 2020 , 125, 83-93	41
408	Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia. 2020 , 46, 811-817	7
407	The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer. 2020 , 20, 95-100	14
406	Patient outcome according to the 2017 international consensus on the definition of borderline resectable pancreatic ductal adenocarcinoma. 2020 , 20, 223-228	7
405	FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma. 2020 , 12, 1758835920953294	9
404	Stage-Specific Value of Carbohydrate Antigen 19-9 and Carcinoembryonic Antigen Serum Levels on Survival and Recurrence in Pancreatic Cancer: A Single Center Study and Meta-Analysis. 2020 , 12,	6
403	Press review. 2020 , 157, 341-348	78
402	Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review. 2020 , 91, 102110	3
401	Glycogen synthase kinase-3 β participates in acquired resistance to gemcitabine in pancreatic cancer. 2020 , 111, 4405-4416	3
400	Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. 2020 , 27, 4348-4359	9
399	A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. 2020 , 49, 904-911	2
398	Hepatic Steatosis After Neoadjuvant Chemotherapy for Pancreatic Cancer: Incidence and Implications for Outcomes After Pancreatoduodenectomy. 2020 , 24, 2008-2014	0
397	A Case of Pathological Complete Response Following FOLFIRINOX Therapy for Pancreatic Adenocarcinoma with Synchronous Distant Lymph Node Metastases. 2020 , 72, 471-476	3
396	Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. 2020 , 70, 375-403	72

395	A Narrative Review of Regional Hyperthermia: Updates From 2010 to 2019. 2020 , 19, 1534735420932648	9
394	Chemotherapy-based split stereotactic body radiation therapy for borderline resectable and locally advanced pancreatic cancer: study protocol of a prospective, single-arm phase II trial. 2020 , 10, e039900	0
393	Duktales Adenokarzinom des Pankreas [Entstehung, Diagnostik, Therapie]. 2020 , 26, 977-985	
392	Endosonography-guided Radiofrequency Ablation in Pancreatic Diseases: Time to Fill the Gap Between Evidence and Enthusiasm. 2020 , 54, 591-601	4
391	Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. 2020 , 10, 1112	5
390	Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?. 2020 , 12, 1758835920936093	15
389	Immunological combination treatment holds the key to improving survival in pancreatic cancer. 2020 , 146, 2897-2911	5
388	Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. 2020 , 152, 63-69	9
387	Nationwide compliance with a multidisciplinary guideline on pancreatic cancer during 6-year follow-up. 2020 , 20, 1723-1731	3
386	FOLFIRINOX for Recurrent Pancreatic Cancer After Pancreatic Resection: A Secondary Analysis of the Nationwide Multicenter Observational Study Conducted by the Japan Adjuvant Study Group of Pancreatic Cancer 06. 2020 , 49, 1372-1377	
385	Treatment Strategies for the Optimal Management of Locally Advanced Pancreatic Adenocarcinoma With Curative Intent: A Systematic Review. 2020 , 49, 1264-1275	2
384	[Indications for Surgery in Pancreatic Ductal Adenocarcinoma - Consensus Recommendations by the German Society for General and Visceral Surgery]. 2020 , 145, 354-364	0
383	Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison. 2020 , 31, 1600-1608	10
382	Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy. 2020 , 2020, 5701949	11
381	Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. 2020 , 122, 1595-1603	4
380	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. 2020 , 6, 1733-1740	29
379	Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. 2020 , 5,	23
378	Efficacy and feasibility of proton beam radiotherapy using the simultaneous integrated boost technique for locally advanced pancreatic cancer. 2020 , 10, 21712	3

377	Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress. 2020 , 13, 12705-12720	3
376	Evaluation of the In Vitro Cytotoxic Activity of Caffeic Acid Derivatives and Liposomal Formulation against Pancreatic Cancer Cell Lines. 2020 , 13,	4
375	FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?. 2020 , 5, e000633	1
374	Advances and challenges of neoadjuvant therapy in pancreatic cancer. 2021 , 17, 425-434	2
373	Duration of therapy for locally advanced pancreatic cancer: Does it matter?. 2020 , 9, 4572-4580	2
372	Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. 2020 , 9, 4711-4723	15
371	Impact of neoadjuvant therapy on post-operative pancreatic fistula: a systematic review and meta-analysis. 2020 , 90, 2201-2210	9
370	Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFB activation. 2020 , 127, 110116	9
369	Pancreatic Cancer Imaging: What the Surgeon Wants to Know?. 2020 , 3, 040-052	
368	The abrupt pancreatic duct cutoff sign on MDCT and MRI. 2020 , 45, 2476-2484	2
367	Antifibrotic therapy to normalize the tumor microenvironment. 2020 , 18, 207	25
366	Rapid Cancer Diagnosis and Early Prognosis of Metastatic Risk Based on Mechanical Invasiveness of Sampled Cells. 2020 , 48, 2846-2858	10
365	Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer. 2020 , 20, 919-928	12
364	Recapitulating pancreatic tumor microenvironment through synergistic use of patient organoids and organ-on-a-chip vasculature. 2020 , 30, 2000545	24
363	The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis. 2020 , 24, 6-16	2
362	Neoadjuvant Treatment in Pancreatic Cancer. 2020 , 10, 245	58
361	ASO Author Reflections: Neoadjuvant Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma-Predictors of Disease Progression and Performance Status Decline. 2020 , 27, 2972-2973	
360	Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy. 2020 , 59, 944-948	1

359	How to Approach Para-Aortic Lymph Node Metastases During Exploration for Suspected Periampullary Carcinoma: Resection or Bypass?. 2020 , 27, 2949-2958	2
358	Metabolism of pancreatic cancer: paving the way to better anticancer strategies. 2020 , 19, 50	62
357	Irreversible electroporation after induction chemotherapy versus chemotherapy alone for patients with locally advanced pancreatic cancer: A propensity score matching analysis. 2020 , 20, 477-484	14
356	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. 2020 , 123, 709-713	13
355	Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. 2020 , 49, 822-829	1
354	Recurrence Patterns for Pancreatic Ductal Adenocarcinoma after Upfront Resection Versus Resection Following Neoadjuvant Therapy: A Comprehensive Meta-Analysis. 2020 , 9,	6
353	Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. 2020 , 20, 1131-1138	11
352	Inactivation of APC Induces CD34 Upregulation to Promote Epithelial-Mesenchymal Transition and Cancer Stem Cell Traits in Pancreatic Cancer. 2020 , 21,	8
351	Albendazole suppresses cell proliferation and migration and induces apoptosis in human pancreatic cancer cells. 2020 , 31, 431-439	10
350	Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. 2020 , 10, 6	11
349	Neoadjuvant Treatment in Patients With Resectable and Borderline Resectable Pancreatic Cancer. 2020 , 10, 41	24
348	Tumor Regression Grading Assessment in Locally Advanced Pancreatic Cancer After Neoadjuvant FOLFIRINOX: Interobserver Agreement and Prognostic Implications. 2020 , 10, 64	4
347	Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. 2020 , 10, e495-e507	20
346	Charging forward in locally advanced pancreatic cancer. 2020 , 5, 234-236	2
345	Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma. 2020 , 75, 478.e1-478.e11	2
344	Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study. 2020 , 5, 285-294	75
343	Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline Mutation. 2020 , 38, 1378-1388	136
342	Proposal of predictive model on survival in unresectable pancreatic cancer receiving systemic chemotherapy. 2020 , 11, 1223-1230	0

341	Conversion Surgery for Pancreatic Cancer-The Impact of Neoadjuvant Treatment. 2019 , 9, 1501	12
340	Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study. 2020 , 10, 7048	21
339	ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy in unresected pancreatic cancer. 2020 , 148, 57-64	1
338	Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?. 2020 , 9,	16
337	Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer. 2020 , 27, 3963-3970	22
336	Predictors of Disease Progression or Performance Status Decline in Patients Undergoing Neoadjuvant Therapy for Localized Pancreatic Head Adenocarcinoma. 2020 , 27, 2961-2971	5
335	Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population. 2021 , 62, 164-171	3
334	Dilemma and Challenge of Immunotherapy for Pancreatic Cancer. 2021 , 66, 359-368	15
333	Synchronous arterial resections in pancreatic cancer - still a matter of debate?. 2021 , 47, 480-482	5
332	Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy. 2021 , 28, 1106-1108	8
331	The Effect of Disclosing Life Expectancy Information on Patients' Prognostic Understanding: Secondary Outcomes From a Multicenter Randomized Trial of a Palliative Chemotherapy Educational Intervention. 2021 , 61, 1-11.e3	5
330	Prognostic factors in patients with locally advanced or borderline resectable pancreatic ductal adenocarcinoma: chemotherapy vs. chemoradiotherapy. 2021 , 46, 655-666	2
329	Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients. 2021 , 147, 661-667	2
328	Factors predicting survival in patients with locally advanced pancreatic cancer undergoing pancreatectomy with arterial resection. 2021 , 73, 233-249	4
327	Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection. 2021 , 257, 605-615	4
326	Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. 2021 , 34, 4-12	12
325	Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients. 2021 , 26, 543-551	4
324	Laser Treatment of Pancreatic Cancer with Immunostimulating Interstitial Laser Thermotherapy Protocol: Safety and Feasibility Results From Two Phase 2a Studies. 2021 , 259, 1-7	6

323	Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106. 2021 , 51, 235-243	6
322	SPARC, a phase-I trial of pre-operative, margin intensified, stereotactic body radiation therapy for pancreatic cancer. 2021 , 155, 278-284	0
321	Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. 2021 , 32, 183-196	11
320	Nanoscale platform for delivery of active IRINOX to combat pancreatic cancer. 2021 , 330, 1229-1243	4
319	A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome. 2021 , 155, 232-236	5
318	Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. 2021 , 47, 699-707	4
317	Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX. 2021 , 31, 3616-3626	3
316	Radiosensitization of human pancreatic cancer by piperlongumine analogues. 2021 , 32, 1197-1201	7
315	Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. 2021 , 6, 100621	3
314	CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. 2021 , 31, 3383-3393	4
313	R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007 ² trial. 2021 , 197, 8-18	9
312	CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. 2021 , 31, 813-823	9
311	Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis. 2021 , 273, 587-594	31
310	Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. 2021 , 273, 341-349	121
309	Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. 2021 , 273, 579-586	59
308	Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. 2021 , 273, 1173-1181	24
307	The treatment and survival of elderly patients with locally advanced pancreatic cancer: A post-hoc analysis of a multicenter registry. 2021 , 21, 163-169	3
306	Prognostic Factors in Patients With Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Resection. 2021 , 3134821991962	1

305	Radiosensitizing Pancreatic Cancer with PARP Inhibitor and Gemcitabine: An In Vivo and a Whole-Transcriptome Analysis after Proton or Photon Irradiation. 2021 , 13,	3
304	Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results. 2021 , 16, 3	3
303	Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery?. 2021 , 12, 2450-2460	1
302	Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer. 2021 , 51, 1727-1732	1
301	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer. 2021 , 61-74	
300	Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer. 2021 , 51-60	
299	Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology. 2021 , 12, 2475-2483	0
298	Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. 2021 , 8, 2002147	14
297	Role of Ablation Technologies in Locally Advanced Pancreatic Cancer. 2021 , 1267-1280	0
296	The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. 2021 , 51, 728-736	1
295	Extended pancreatectomy in patients with pancreatic cancer. 2021 , 36, 82-88	
294	Scoring of tumour response after neoadjuvant therapy in resected pancreatic cancer: systematic review. 2021 , 108, 119-127	3
293	Irreversible electroporation of locally advanced pancreatic cancer. 2021 , 48, 84-94	0
292	Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. 2020 , 10, 622318	2
291	Intention to treat outcomes among patients with pancreatic cancer treated using International Study Group on Pancreatic Surgery recommended pathways for resectable and borderline resectable disease. 2021 , 91, 1549-1557	0
290	Improvement in distal pancreatectomy for tumors in the body and tail of the pancreas. 2021 , 19, 49	1
289	[Diagnostics and therapy of pancreatic carcinoma]. 2021 , 146, 246-252	
288	The Landmark Series: Locally Advanced Pancreatic Cancer and Ablative Therapy Options. 2021 , 28, 4173-4180	1

287	Efficacy of Adjuvant Chemotherapy after Neoadjuvant FOLFIRINOX and Following Resection of Pancreatic Cancer. 2021 , 77, 95-96	
286	Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. 2021 , 6, 128-138	26
285	Comment on "Arterial Resection in Pancreatic Cancer Surgery: Effective After a Learning Curve". 2021 , 274, e882-e884	
284	Impact of multidisciplinary approach and radiologic review on surgical outcome and overall survival of patients with pancreatic cancer: a retrospective cohort study. 2021 , 300891621999092	
283	Survival after Margin-Positive Resection in the Era of Modern Chemotherapy for Pancreatic Cancer: Do Patients Still Benefit?. 2021 , 233, 100-109	3
282	Effect of centralization and regionalization of pancreatic surgery on resection rates and survival. 2021 , 108, 826-833	3
281	Effect and limitation of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma: consideration from a new perspective. 2021 , 19, 85	2
280	Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX. 2021 , 15, 315-323	2
279	Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort. 2021 , 124, 1941-1948	5
278	Development of Facile and Versatile Platinum Drug Delivering Silicasome Nanocarriers for Efficient Pancreatic Cancer Chemo-Immunotherapy. 2021 , 17, e2005993	18
277	Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. 2021 , 21, 300	22
276	The impact of cachexia and sarcopenia in elderly pancreatic cancer patients receiving palliative chemotherapy. 2021 , 26, 1293-1303	5
275	Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King. 2021 , 123, 1395-1404	0
274	Hepatic Artery Infusion of Floxuridine in Combination With Systemic Chemotherapy for Pancreatic Cancer Liver Metastasis: A Propensity Score-Matched Analysis in Two Centers. 2021 , 11, 652426	4
273	The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies. 2021 , 9,	8
272	Contemporary trials evaluating neoadjuvant therapy for resectable pancreatic cancer. 2021 , 123, 1423-1431	1
271	Predicting Surgical Margins in Patients With Borderline Resectable and Locally Advanced Pancreatic Cancer Undergoing Resection. 2021 , 31348211011129	
270	A Patient With Locally Advanced Mismatch-Repair-Deficient Pancreatic Ductal Adenocarcinoma Successfully Treated With Neoadjuvant Immunotherapy. 2021 , 13, e14640	1

269	Irreversible Electroporation (IRE) in Locally Advanced Pancreatic Cancer: A Review of Current Clinical Outcomes, Mechanism of Action and Opportunities for Synergistic Therapy. 2021 , 10,	6
268	Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. 2021 , 11, 615691	0
267	Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer. 2021 , 11, 662205	1
266	Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. 2021 , 12, S110-S117	1
265	Radiofrequency ablation and chemotherapy versus chemotherapy alone for locally advanced pancreatic cancer (PELICAN): study protocol for a randomized controlled trial. 2021 , 22, 313	3
264	A Critical Overview of Systematic Reviews of Chemotherapy for Advanced and Locally Advanced Pancreatic Cancer using both AMSTAR2 and ROBIS as Quality Assessment Tools. 2021 , 16, 180-192	3
263	[Stereotactic body radiotherapy for locally advanced pancreatic cancer: A systemic review]. 2021 , 25, 283-295	2
262	Change in neoadjuvant chemotherapy could alter the prognosis of patients with pancreatic adenocarcinoma: A case report. 2021 , 9, 3418-3423	1
261	Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial. 2021 , 148, 422-429	4
260	Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX. 2021 , 15, 466-475	2
259	Ablation in Pancreatic Cancer: Past, Present and Future. 2021 , 13,	5
258	Association of Ablative Radiation Therapy With Survival Among Patients With Inoperable Pancreatic Cancer. 2021 , 7, 735-738	30
257	A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer. 2021 , 100, e26052	1
256	Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume. 2021 , 25, 2562-2571	1
255	Systemische Therapie des duktaalen Pankreaskarzinoms. 2021 , 24, 37-47	
254	Irreversible Electroporation (IRE) Combined With Chemotherapy Increases Survival in Locally Advanced Pancreatic Cancer (LAPC). 2021 , 44, 325-330	1
253	Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches. 2021 , 21, 1326-1341	1
252	UPF1 promotes chemoresistance to oxaliplatin through regulation of TOP2A activity and maintenance of stemness in colorectal cancer. 2021 , 12, 519	6

251	Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis. 2021 ,	0
250	Usefulness of Imaging Response Assessment after Irreversible Electroporation of Localized Pancreatic Cancer-Results from a Prospective Cohort. 2021 , 13,	0
249	Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. 2021 , 28, 8297-8308	4
248	Survival impact on triple-modal strategy comprising hyperthermia, external radiation, and chemotherapy for unresectable locally advanced (UR-LA) pancreatic ductal adenocarcinoma. 2021 , 37, 101542	1
247	Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer. 2021 , 11,	3
246	Feasibility and efficacy of a multicomponent exercise medicine programme in patients with pancreatic cancer undergoing neoadjuvant therapy (the EXPAN trial): study protocol of a dual-centre, two-armed phase I randomised controlled trial. 2021 , 8,	1
245	Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial. 2021 , 21, 1342-1348	0
244	Advances in the management of pancreatic ductal adenocarcinoma. 2021 , 193, E844-E851	2
243	Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. 2021 , 124, 589-597	2
242	Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells. 2021 , 16, e0252917	2
241	The role of FOLFIRINOX in metastatic pancreatic cancer: a meta-analysis. 2021 , 19, 182	1
240	Gemcitabine/Nab-Paclitaxel versus FOLFIRINOX in Locally Advanced Pancreatic Cancer: A European Multicenter Study. 2021 , 13,	3
239	Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management. 2021 , 27, 3158-3181	4
238	Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review. 2021 , 13,	2
237	Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. 2021 , 44, 469-474	0
236	The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. 2021 , 11, 688377	8
235	Survival Benefit Associated With Resection of Locally Advanced Pancreatic Cancer After Upfront FOLFIRINOX Versus FOLFIRINOX Only: Multicenter Propensity Score-matched Analysis. 2021 , 274, 729-735	2
234	Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement. 2021 , 274, 894-901	5

233	Predictive Value of Neutrophils Count for Local Tumor Control After Chemoradiotherapy in Patients With Locally Advanced Pancreatic Carcinoma. 2021 , 110, 1022-1031	2
232	Effectiveness of Carbon Ion Radiation in Locally Advanced Pancreatic Cancer. 2021 , 11, 708884	0
231	Neoadjuvant treatment for borderline resectable pancreatic adenocarcinoma is associated with higher R0 rate compared to upfront surgery. 2021 , 60, 1114-1121	0
230	Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. 2021 , 28, 8249-8260	5
229	Efficacy and Safety of Neoadjuvant Gemcitabine Plus Nab-Paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Cancer-A Systematic Review and Meta-Analysis. 2021 , 13,	3
228	Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis. 2021 , 14, 101139	1
227	Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreatic adenocarcinoma. 2021 ,	0
226	Improved prognosis of pancreatic cancer patients with peritoneal metastasis. 2021 , 21, 903-911	4
225	Adjuvant Treatment in Pancreatic Cancer: Shaping the Future of the Curative Setting. 2021 , 11, 695627	2
224	Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies. 2021 , 11,	1
223	Direct Endoplasmic Reticulum Targeting by the Selective Alkylphospholipid Analog and Antitumor Ether Lipid Edelfosine as a Therapeutic Approach in Pancreatic Cancer. 2021 , 13,	2
222	Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. 2021 , 13,	5
221	Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?. 2021 , 13,	0
220	Biliary intervention rates during neoadjuvant therapy for adenocarcinoma of the pancreatic head. 2021 , 23, 1196-1200	1
219	Analysis of the Curative Effect of Neoadjuvant Therapy on Pancreatic Cancer. 2021 , 11, 695645	1
218	Evaluation of the In Vitro Cytotoxic Activity of Ursolic Acid PLGA Nanoparticles against Pancreatic Ductal Adenocarcinoma Cell Lines. 2021 , 14,	5
217	Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study). 2021 , 50, 957-964	1
216	. 2021 , 193, E1362-E1370	

215	The role of radiotherapy in locally advanced pancreatic cancer. 2021 , 94, 20210044	
214	Pancreatic cancer in 2021: What you need to know to win. 2021 , 27, 5851-5889	7
213	Successful En Bloc Resection of Locally Advanced Pancreatic Tail Cancer with Colonic Perforation Following Neoadjuvant Chemotherapy: A Case Report. 2021 , 22, e933226	0
212	Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy. 2021 ,	0
211	European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Pancreatic Cancer. 2021 , 99, 102208	1
210	Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. 2021 , 13,	2
209	[Extreme hypofractionated radiation therapy for pancreatic cancer]. 2021 , 25, 692-698	
208	Total neoadjuvant therapy for initially inoperable pancreatic cancer: A systematic review of phase 2-3 studies. 2021 , 164, 13-19	1
207	Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study. 2021 , 28, 1896-1905	2
206	Circulating mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX. 2021 , 13, 17588359211033704	0
205	Cancer du pancr�as. 2021 , 153-190.e3	
204	Imaging After Neoadjuvant Therapy. 2021 , 437-453	0
203	Can local ablative techniques replace surgery for locally advanced pancreatic cancer?. 2021 , 12, 2536-2546	1
202	Preoperative Therapy in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer. 2021 , 729-741	
201	Delta Radiomics Analysis for Local Control Prediction in Pancreatic Cancer Patients Treated Using Magnetic Resonance Guided Radiotherapy. 2021 , 11,	13
200	The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. 2021 , 51, 1099-1107	0
199	Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer. 2021 , 100, e24068	5
198	Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?. 2020 , 72, 321-324	7

197	Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. 2020 , 22, 821-832	22
196	Dendritic cell-based vaccination: powerful resources of immature dendritic cells against pancreatic adenocarcinoma. 2018 , 7, e1504727	2
195	Conversion surgery in patients with initially unresectable pancreatic ductal adenocarcinoma: where do we stand in 2018?. 2018 , 1, 25-29	4
194	A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. 2021 , 45, 394-404	4
193	Pancreatic Cancer: A Time to Change. 2020 , 271, 1003-1004	5
192	A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: The PANAMA-score. 2020 ,	1
191	A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects with Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer. 2020 , 275,	10
190	Irreversible JNK1-JUN inhibition by JNK-IN-8 sensitizes pancreatic cancer to 5-FU/FOLFOX chemotherapy. 2020 , 5,	14
189	Possibilities of palliative chemotherapy in patients with locally advanced and metastatic pancreatic cancer. 2020 , 7, 118-134	1
188	Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. 2017 , 8, 46337-46347	29
187	Neoadjuvant photodynamic therapy augments immediate and prolonged oxaliplatin efficacy in metastatic pancreatic cancer organoids. 2018 , 9, 13009-13022	26
186	Intensification of induction chemotherapy before consolidation chemoradiotherapy improves progression-free survival and time without treatment in patients with locally advanced pancreatic cancers. 2018 , 9, 31999-32009	1
185	Comparison of Quality of Life before and after pancreaticoduodenectomy: a prospective study. 2018 , 10, 7054-7062	4
184	Novel therapeutic approaches for pancreatic cancer by combined targeting of RAF-MEK-ERK signaling and autophagy survival response. 2019 , 7, S153	12
183	Can we downstage locally advanced pancreatic cancer to resectable? A phase I/II study of induction oxaliplatin and 5-FU chemoradiation. 2018 , 9, 922-935	3
182	Pancreatic cancer in Australia: is not it time we address the inequitable resource problem?. 2020 , 16, 1385-1392	3
181	Ablation treatments in unresectable pancreatic cancer. 2019 , 74, 263-269	4
180	Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer. 2020 , 75, 15-24	2

179	Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. 2020 , 12,	8
178	Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study. 2017 , 49, 1022-1032	7
177	Evolving treatment landscape for early and advanced pancreatic cancer. 2017 , 9, 281-292	19
176	Endoscopic Palliation for Biliary and Pancreatic Malignancies: Recent Advances. 2019 , 52, 226-234	13
175	Patient Satisfaction and Quality of Life Before and After Treatment of Pancreatic and Periampullary Cancer: A Prospective Multicenter Study. 2020 , 18, 704-711	3
174	Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach. 2018 , 10, e2324	11
173	Investigation of Conversion Surgery for Initial UR-PDAC: Is Adjuvant Chemotherapy Still Necessary?. 2021 , 54, 665-678	
172	Artificial Intelligence-Based Segmentation of Residual Tumor in Histopathology of Pancreatic Cancer after Neoadjuvant Treatment. 2021 , 13,	0
171	Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities. 2021 , 27, 6572-6589	4
170	A personalized approach to pancreatic ductal adenocarcinoma and its application in surgical practice. 2021 , 18, 613-627	0
169	Up-regulation of S100P predicts the poor long-term survival and construction of prognostic signature for survival and immunotherapy in patients with pancreatic cancer. 2021 , 12, 9006-9020	1
168	Serum miR-373-3p and miR-194-5p Are Associated with Early Tumor Progression during FOLFIRINOX Treatment in Pancreatic Cancer Patients: A Prospective Multicenter Study. 2021 , 22,	3
167	Communicating the Information Needed for Treatment Decision Making Among Patients With Pancreatic Cancer Receiving Preoperative Therapy. 2021 , OP2100388	0
166	Efficient nano-enabled therapy for gastrointestinal cancer using silicasome delivery technology. 2021 , 64, 1946	4
165	Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map?. 2016 , 5, S243-S247	1
164	Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. 2017 , 54, 530-534	0
163	Traitement chirurgical de l'adénocarcinome pancréatique en 2017: sélection des malades, sélection de la tumeur et préparation à l'intervention, innovations techniques, rôle de l'effet centre. 2017 , 201, 245-258	
162	Borderline Resectable Pancreatic Cancer. 2017 , 1-21	

- 161 Chemotherapy in the Management of Pancreatic Cancer. **2017**, 387-419
- 160 Pancreatic Resection After Neoadjuvant Treatment. **2017**, 221-229
- 159 Neoadjuvant Chemotherapy in Pancreatic Cancer. **2017**, 1-16
- 158 The Management of Locally Advanced Nonmetastatic Pancreas Cancer. **2018**, 183-204
- 157 Staging and Prognostic Implications. **2018**, 109-118
- 156 Treatment strategy for unresectable pancreatic cancer. **2018**, 33, 37-47
- 155 Combined therapy with gemcitabine hydrochloride and nanoparticle albumin-bound paclitaxel enabled resection in a patient with unresectable locally advanced pancreatic cancer. **2018**, 33, 776-783
- 154 Stereotactic Body Radiation Therapy for Gastrointestinal Cancers. **2019**, 277-288
- 153 [Pure laparoscopic DP-CAR procedure with portal vein resection]. **2019**, 93-98
- 152 Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?. **2021**, 1 0
- 151 Induction FOLFIRINOX for patients with locally unresectable pancreatic ductal adenocarcinoma. **2021**, 1 1
- 150 Diagnostik und Therapie des Pankreaskarzinoms. **2021**, 42, 655-661
- 149 Pancreatic Cancer: Statistics And Treatment In The Russian Federation. **2020**, 9,
- 148 Commentary: Two papers, 2 tumor types, same conclusion. **2020**, 168, 1019-1020
- 147 Duktales Adenokarzinom des Pankreas [Entstehung, Diagnostik, Therapie. **2021**, 16, 41-50 0
- 146 Indian Council of Medical Research Consensus Document for the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. **2020**, 41, 166-172
- 145 Pancreatic cancer treatment. **2020**, 35, 193-200
- 144 How open is the therapeutic horizon for pancreatic cancer patients?. **2021**, 21, 1-1 1

143	LncRNA C9orf139 can regulate the growth of pancreatic cancer by mediating the miR-663a/Sox12 axis. 2020 , 12, 1272-1287	3
142	Implantation of a neoantigen-targeted hydrogel vaccine prevents recurrence of pancreatic adenocarcinoma after incomplete resection. 2021 , 10, 2001159	1
141	Quality of life of locally advanced pancreatic cancer patients after FOLFIRINOX treatment. 2021 , 1	0
140	Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: Role of the Radiologist and Oncologist in the Era of Precision Medicine. 2021 , 11,	3
139	Diagnostik und Therapie des Pankreaskarzinoms. 2021 , 12, 265-271	
138	Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS. 2021 , 1188, 123075	0
137	Finding a role for cancer vaccines in pancreatic cancer: a model of resilience.. 2022 , 11, 115-118	1
136	A novel event-free survival endpoint in locally advanced pancreatic cancer. 2021 , 13, 17588359211059586	
135	Extracellular Vesicles from Pancreatic Cancer Stem Cells Lead an Intratumor Communication Network (EVNet) to fuel tumour progression.. 2022 ,	3
134	Comment on "Pancreatectomy With Arterial Resection for Pancreatic Adenocarcinoma: How Can It Be Done Safely and With Which Outcomes?". 2021 , 274, e814-e815	
133	Competing Risk Analysis of Outcomes of Unresectable Pancreatic Cancer Patients Undergoing Definitive Radiotherapy.. 2021 , 11, 730646	
132	Beneficial role of electrochemotherapy in locally advanced pancreatic cancer - radiological perspective.. 2022 , 87, e30-e42	0
131	Gastrointestinal System Cancers. 2022 , 411-461	
130	Evolving pancreatic cancer treatment: From diagnosis to healthcare management.. 2021 , 169, 103571	2
129	A non-surgical COMBO-therapy approach for locally advanced unresectable pancreatic adenocarcinoma: preliminary results of a prospective study.. 2022 , 127, 214	3
128	Intra-Arterial Infusion Chemotherapy in Advanced Pancreatic Cancer: A Comprehensive Review.. 2022 , 14,	0
127	Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival.. 2021 , 11, 817220	0
126	FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery (TAPS) Consortium.. 2022 ,	2

125	Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling.. 2022 , 38, 20-29	1
124	Total neoadjuvant therapy for pancreatic adenocarcinoma increases probability for a complete pathologic response.. 2022 ,	1
123	Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?. 2022 ,	0
122	Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis.. 2022 , 104, 102338	1
121	Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.. 2022 , 17, 32	1
120	A locally advanced pancreatic body cancer presenting common bile duct invasion resected via distal pancreatectomy after gemcitabine plus nab-paclitaxel chemotherapy: A case report.. 2022 , 92, 106818	1
119	Drug treatment for chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.. 2022 , 68,	
118	Potentially curative resection of an abdominal wall metastasis from pancreatic adenocarcinoma: a case report.. 2022 , 2022, rjac138	1
117	Safety and Efficacy of S-IROX (S-1, Irinotecan And Oxaliplatin Combination Therapy) in Patients with Advanced Pancreatic Cancer: A Multicenter Phase 1b Dose-Escalation and Dose-Expansion Clinical Trial.	
116	Endoscopic Management of Pancreatobiliary Malignancies.. 2022 ,	0
115	Synchronous double primary malignancies of the pancreatic body and extrahepatic bile duct treated with pancreatoduodenectomy and splenic artery resection following neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel: a case report.. 2022 , 8, 29	0
114	Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched Analysis.. 2022 , 14,	0
113	[Surgical treatment of pancreatic cancer-What is new?]. 2022 , 1	1
112	Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.. 2022 ,	
111	Rintatolimod (Ampligen) Enhances Numbers of Peripheral B Cells and Is Associated with Longer Survival in Patients with Locally Advanced and Metastasized Pancreatic Cancer Pre-Treated with FOLFIRINOX: A Single-Center Named Patient Program.. 2022 , 14,	
110	Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer.. 2022 , 12, 782730	1
109	Pharmacological Modulation of Apoptosis and Autophagy in the Treatment of Pancreatic Cancer.. 2022 ,	0
108	Upregulation of PODXL and ITGB1 in pancreatic cancer tissues preoperatively obtained by EUS-FNAB correlates with unfavorable prognosis of postoperative pancreatic cancer patients.. 2022 , 17, e0265172	0

107	Multi-Agent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.. 2022,	0
106	Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.. 2022, 10,	0
105	Computed tomography-based radiomic to predict resectability in locally advanced pancreatic cancer treated with chemotherapy and radiotherapy.. 2022, 14, 703-715	0
104	Local Ablative Therapy Associated with Immunotherapy in Locally Advanced Pancreatic Cancer: A Solution to Overcome the Double Trouble?-A Comprehensive Review.. 2022, 11,	1
103	Recent advances in targeted drug delivery for the treatment of pancreatic ductal adenocarcinoma.. 2022, 1-21	0
102	Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment.. 2022,	1
101	Cetuximab, gemcitabine and radiotherapy in locally advanced pancreatic cancer: Long-term results of the randomized controlled phase II PARC trial.. 2022, 34, 15-22	2
100	Current status of non-surgical treatment of locally advanced pancreatic cancer.. 2021, 13, 2064-2075	2
99	An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer.. 2021,	0
98	Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence.. 2021,	0
97	Lysosome-targeted drug combination induces multiple organelle dysfunctions and non-canonical death in pancreatic cancer cells.. 2022, 47,	0
96	Perioperative and long-term outcome of en-bloc arterial resection in pancreatic surgery.. 2021,	
95	Imaging-based Machine-learning Models to Predict Clinical Outcomes and Identify Biomarkers in Pancreatic Cancer: A Scoping Review.. 2021, 275,	1
94	Image_1.JPEG. 2020,	
93	Prognostic Significance of Intraoperative Peritoneal Lavage Cytology in Patients with Pancreatic Ductal Adenocarcinoma: A Single-Center Experience and Systematic Review of the Literature.. 2022 , 1	1
92	Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?. 2022, 12,	0
91	Endoscopic Ultrasound-Guided Laser Ablation Using a Diffusing Applicator for Locally Advanced Pancreatic Cancer Treatment.. 2022, 14,	0
90	Treatment of unresectable locally advanced pancreatic cancer with percutaneous irreversible electroporation (IRE) following initial systemic chemotherapy (LAP-PIE) trial: study protocol for a feasibility randomised controlled trial.. 2022, 12, e050166	0

89	Systemic Therapies for Pancreatic Cancer. 2022 , 193-200	
88	Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer.	1
87	Neoadjuvant Treatment in Resectable Pancreatic Cancer. Is It Time for Pushing on It?. 12,	1
86	Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review. 2022 , 14, 2486	3
85	The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer. 12,	0
84	Prediction of Margin-Negative Resection of Pancreatic Ductal Adenocarcinoma Following Neoadjuvant Therapy: Diagnostic Performance of NCCN Criteria for Resection vs. CT-Determined Resectability.	
83	Trends in the surgical treatment for pancreatic cancer in the last 30 years. 2022 ,	
82	Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. 2022 , 17,	1
81	S3-Leitlinie zum exokrinen Pankreaskarzinom [Kurzversion 2.0 Dezember 2021, AWMF-Registernummer: 032/010OL. 2022 , 60, 991-1037	0
80	Patency rates of hepatic arterial resection and revascularization in locally advanced pancreatic cancer. 2022 ,	1
79	Safety and tumour-specific immunological responses of combined dendritic cell vaccination and anti-CD40 agonistic antibody treatment for patients with metastatic pancreatic cancer: protocol for a phase I, open-label, single-arm, dose-escalation study (REACTiVe-2 trial). 2022 , 12, e060431	0
78	Biodegradable Ultrasmall-in-Nano Architectures Loaded with Cisplatin Prodrug in Combination with Ionizing Radiation Induces DNA Damage and Apoptosis in Pancreatic Ductal Adenocarcinoma. 2022 , 14, 3034	0
77	Novel 5-Fluorouracil Carbonate-Loaded Liposome: Preparation, In Vitro, and In Vivo Evaluation as an Antitumor Agent.	
76	DESTRUCTION OF TUMOR MICROENVIRONMENT AS A PROMISING TREATMENT APPROACH IN PANCREATIC CANCER.	
75	Treatment Response and Conditional Survival in Advanced Pancreatic Cancer Patients Treated with FOLFIRINOX: A Multicenter Cohort Study. 2022 , 2022, 1-9	0
74	Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and network meta-analysis protocol. 2022 , 12, e050558	0
73	Multimodal Therapies Against Pancreatic Ductal Adenocarcinoma: A Review on Synergistic Approaches Towards Ultimate Nanomedicine Treatments. 2200079	2
72	Phase I Trial of nab-Paclitaxel Administered Concurrently With Radiotherapy in Patients With Locally Advanced Inoperable Pancreatic Adenocarcinoma. Publish Ahead of Print,	

71	Postoperative Chemotherapy is Associated with Improved Survival in Patients with Node-Positive Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy.	0
70	Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study.	0
69	Serum cytokine levels are associated with tumor progression during FOLFIRINOX chemotherapy and overall survival in pancreatic cancer patients. 13,	0
68	Comparison of Regional Arterial Chemotherapy and Systemic Intravenous Chemotherapy for Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. Publish Ahead of Print,	
67	Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113). 2022 , 7, 100552	1
66	Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic Cancer. 2022 , 20, 887-897.e3	0
65	Advances in the Surgical Treatment of Pancreatic Cancer. 2022 ,	
64	Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer. 12,	0
63	Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. 2022 , 174, 102-112	0
62	Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial. 2022 , 174, 40-47	
61	A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma (PDAC).	0
60	Regulation of pancreatic cancer therapy resistance by chemokines. 2022 , 86, 69-80	2
59	Total Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma Is Associated With Limited Lymph Node Yield but Improved Ratio. 2022 , 280, 543-550	0
58	Predictive factors for early recurrence after pancreaticoduodenectomy in patients with resectable pancreatic head cancer: A multicenter retrospective study. 2022 ,	0
57	Preliminary Development and Testing of C595 Radioimmunoconjugates for Targeting MUC1 Cancer Epitopes in Pancreatic Ductal Adenocarcinoma. 2022 , 11, 2983	0
56	Neoadjuvant Chemotherapy-Chemoradiation for Borderline-Resectable Pancreatic Adenocarcinoma: A UK Tertiary Surgical Oncology Centre Series. 2022 , 14, 4678	1
55	Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis.	1
54	Pancreatic Adenocarcinoma Management.	4

53	Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. 2022 , 14, 4360	1
52	Efficacy and safety of traditional Chinese medicine for the treatment of pancreatic cancer: An overview of systematic reviews and meta-analyses. 13,	0
51	Management of Locally Advanced/Metastatic Disease: Medical Oncology. 2022 , 97-106	0
50	Safety and efficiency of combination treatment including high-intensity focused ultrasound therapy in patients with pancreatic cancer. 2022 , 11, 11	0
49	Unusual dMMR Phenotype Locally Advanced Pancreatic Ductal Adenocarcinoma with Germline and Somatic BRCA2 Mutation in a Jehovah Witness Patient. 2022 ,	0
48	Irreversible electroporation of the pancreas [A decade on. 2022 ,	0
47	Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system. 2022 , 24, 88-94	0
46	Locally advanced pancreatic cancer - a complete morpho-metabolic response of primary tumor after non-surgical treatment. 2022 , 16, 268-272	0
45	Practice-oriented solutions integrating intraoperative electron irradiation and personalized proton therapy for recurrent or unresectable cancers: Proof of concept and potential for dual FLASH effect. 12,	0
44	S3-Leitlinie zum exokrinen Pankreaskarzinom [Langversion 2.0 [Dezember 2021] [AWMF-Registernummer: 032/010OL. 2022 , 60, e812-e909	0
43	Prognostic Impact of Positive Peritoneal Lavage Cytology on Resectable Pancreatic Body and Tail Cancer: A Retrospective Study.	0
42	Development of doped ZnO-based biomimicking and tumor-targeted nanotheranostics to improve pancreatic cancer treatment. 2022 , 13,	1
41	Consolidatory ablative stereotactic body radiation therapy after induction chemotherapy for unresectable pancreatic cancer: A single center experience. 12,	0
40	Pancreatic cancers. 2022 , 315-340	0
39	Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. 2022 , 7,	1
38	Neoadjuvant chemotherapy and radiotherapy outcomes in borderline-resectable and locally-advanced pancreatic cancer patients.	0
37	Surgical and Oncological Outcomes After Preoperative FOLFIRINOX Chemotherapy in Resected Pancreatic Cancer: An International Multicenter Cohort Study.	0
36	Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study. 2023 , 15, 7	2

- 35 Induction FOLFIRINOX followed by stereotactic body radiation therapy in locally advanced pancreatic cancer. 12, ○
- 34 A randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). 2022, ○
- 33 Irreversible electroporation for the management of pancreatic cancer: Current data and future directions. 29, 223-231 ○
- 32 Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. 2023, 12, 465 ○
- 31 Clinical Implications of FDG-PET in Pancreatic Ductal Adenocarcinoma Patients Treated with Neoadjuvant Therapy. ○
- 30 A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma. 2023, 181, 119-134 ○
- 29 Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Cancer According to the 2017 International Consensus for Survival and Recurrence in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Upfront Surgery. ○
- 28 High Intensity Focused Ultrasound Ablation for Patients With Locally Advanced Pancreatic Adenocarcinoma. ○
- 27 Stomach and duodenum dose-volume constraints for locally advanced pancreatic cancer patients treated in 15 fractions in combination with chemotherapy. 12, ○
- 26 Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. 2023, 15, 738 ○
- 25 Clinical benefit of subsequent chemotherapy after drug-induced interstitial lung disease in pancreatic cancer patients: a multicenter retrospective study from Japan. 2023, 23, ○
- 24 Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis. 2023, 23, ○
- 23 Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival. 2023, 35, e303-e311 ○
- 22 Ultrasound and Microbubbles Increase the Uptake of Platinum in Murine Orthotopic Pancreatic Tumors. 2023, 49, 1275-1287 ○
- 21 Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX in the LAPC-2 trial. 2023, 183, 1095-1101 ○
- 20 Treatment of pancreatic cancer in 2022. 2023, 1, ○
- 19 Interplay between tumor-derived factors and tumor-associated neutrophils: opportunities for therapeutic interventions in cancer. ○
- 18 Editorial: Surgical Advances in Pancreaticobiliary Diseases. 2023, 12, 1268 ○

- 17 Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF- β signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors. **2023**, 14,
- 16 Research trends and hotspots of neoadjuvant therapy in pancreatic cancer: a bibliometric analysis based on the Web of Science Core Collection.
- 15 Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters. **2023**, 12, 55-61
- 14 A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer.
- 13 Contemporary Treatment Paradigms are Associated with Improved Survival in Pancreatic Cancer. 000313482311578
- 12 Sono-promoted drug penetration and extracellular matrix modulation potentiate sonodynamic therapy of pancreatic ductal adenocarcinoma. **2023**, 161, 265-274
- 11 Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer. **2023**,
- 10 Therapeutic drug monitoring of neoadjuvant mFOLFIRINOX in resected pancreatic ductal adenocarcinoma. **2023**,
- 9 Neoadjuvant therapy for pancreatic cancer.
- 8 Intraoperative Radiation Therapy for Gastrointestinal Malignancies. **2023**,
- 7 FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review.
- 6 Sex and gender differences in treatment intention, quality of life and performance status in the first 100 patients with periampullary cancer enrolled in the CHAMP study. **2023**, 23,
- 5 Combined CT and serum CA19-9 for stratifying risk for progression in patients with locally advanced pancreatic cancer receiving intraoperative radiotherapy. 13,
- 4 DPP10-AS1-Mediated Downregulation of MicroRNA-324-3p Is Conducive to the Malignancy of Pancreatic Cancer by Enhancing CLDN3 Expression. **2022**, 51, 1201-1210
- 3 Predicting conversion surgery in patients with locally advanced pancreatic cancer after modified FOLFIRINOX treatment. **2023**,
- 2 Percutaneous irreversible electroporation in locally advanced pancreatic cancer: A review and a case report. **2023**, 13, 45-53
- 1 Preoperative treatments in borderline resectable and locally advanced pancreatic cancer: Current evidence and new perspectives. **2023**, 186, 104013